Clinical Trial Update: Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics and pharmacodynamics study of linagliptin (BI 1356) 5 mg in African American patients with Type 2 diabetes mellitus; the trial is compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Tradjenta (Linagliptin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED | Results posted: 2011-11-10